Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seasoned executive team with a track record of medical biotechnology innovation... To deliver on its mission, MyMD has assembled a superb team of clinicians, experienced drug developers, US FDA / regulatory experts, patent attorneys, and business executives. The team is drawn from a variety of institutions including but not limited to Organon, Regeneron, IQVIA (formerly Quintiles), Bain & Company, and Banner Witcoff. We continue to add clinical and scientific talent to support our research and the discovery of new therapies.
MyMD Pharmaceuticals Begins Trading on Nasdaq.. . FLASH... FLASH... Phase II Trial results expected by year end . “The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and our clinical development pipeline, all of which should lead to increased visibility in the near term for our investors.. . https://www.businesswire.com/news/home/20210419005502/en/MyMD-Pharmaceuticals-Begins-Trading-on-Nasdaq
MyMD is a clinical-stage pharmaceutical company focused on the development of drug products that represent a transformation in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety and sleep disorders. Our team has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the first drug being designed to significantly increase human lifespan.
https://www.mymd.com
A remarkably bold statement found at the top of the company's web page.
WHAT HATH JONNIE WROUGHT !! I am blown away by the quality of this Scientific Discovery Board. It not only includes a healthy number of Johns Hopkins doctors, but also includes MINDMED and Eurofins Discovery.
Hopefully, MyMD Pharmaceuticals will become a public reality by the end of this week, and we can begin to share this awesome story much more widely than has been the case up to now.
knuts, The main difference is MyMD-1 is ready to use now and has been completed pre-clinical and phase-1 and already entered into Phase-2. Where as Cohbar is still at initial stages and long way to go. . Once Phase-2 is complete, which is by the year end, no one can compete with MyMD in those line. My two cent..
Hard to believe! On 03/11/21 Jonnie and friends created yet another FL private company, this one called Arica Pharmaceuticals. Beginning to look like they are creating a company for each potential application of the isomyosmine and Supera families!
From a competitive point of view I see Jonnie as being ahead because he is ready to begin significant Phase 2 studies, and has chosen company and product names (MyMD Pharmaceuticals and MYMD-1) that are easily recognized and remembered.
Those who are serious about MyMD Pharma should take a look at CohBar. (CWBR) Looks like it could be direct competition for MyMD. They are making many of the same claims as MyMD makes for MYMD-1.
Correction of my previous post. Jonnie Williams appears more than once in the document describing the merger. My earlier search seems to have been defective.
If a new pdf of the document is made, at least on a Mac, it becomes possible to cut text from it and paste it elsewhere.
A section beginning on page 122 describes the reasons for the merger from the point of view of each of the companies.
Today I received a request for my votes (virtually) at the next AKER board meeting, scheduled for April 15, 2021.
It was suggested that I should first read an accompanying background document of somewhere around 400 pages. It contains things that look interesting. I'll read some of it.
Under this heading: "The obligation of Akers to complete the merger is subject to the satisfaction or waiver of the following additional conditions:" This appears as one of the conditions:
Akers shall have received an executed support agreement from Jonnie R. Williams, Sr.
This is the only mention of Williams in the entire document.
The document is probably available only to shareholders. It is not possible to cut and paste from it.
Leif, Agree. But, Shelf offerings can dilute existing shares considerably if the offering comes from the company because new shares are being created. Why a Shell company AKERS is doing this by misguiding public is my concern.
You may be right, but not this is not an announcement of an actual raise, it is an announcement of permission to raise should they need to do so. Nothing is for sale yet. This is how I understand a "shelf offering." Please correct this if I'm wrong.
$AKER: The reasons mentioned to raise $100 millions is full of lies. Issuing another public offering (in the last minute of merger with MyMD pharma) to raise for non-existing covid-19 vaccine is federal crime. Raising $100 Millions in the name of agreement with a non performing Premas (which is an INDIA company) is federal fraud. Raising the money in the last minute of merger is another definitely unacceptable & its a BIG fraud, very bad for investors. The AKERS present directors have to face the consequences... Something is not right.
Could be wrong, of course, but I think the merger with MYMD will succeed. There's too much benefit here for AKER to allow it to fail. Main reason for my confidence is that I think Jonnie Williams' work and intentions are genuine. His long-standing collaboration with Johns Hopkins researchers is encouraging.
After the merger, the surviving company will be MYMD, and the stock listing will be MYMD. I'm optimistic that this will be a success.
The "Registered Agent" for most (all?) of these companies is James A. McNulty (CPA), at 324 S. Hyde Park Avenue, Tampa, FL, 33606. A search on that address, leads to ...
I rarely spend this much time looking for info on a small company like AKER. However, I have an intuition that something important is going on here, and that Jonnie Williams is the driver. What he did with Star Scientific was important and unjustly attacked and destroyed by politically & economically connected interests (my opinion, of course).
A little further search finds that Francis E. O'Donnell is closely connected with McNulty, and that all of them are related to a number of companies containing words like "Hopkins Capital Group" in their titles. All (or most) of these companies are connected to Jonnie Williams.
Please don't make too much of all this. I am in no way a professional analyst of businesses. I'm interested because of good experiences with Anatabloc, and because I hope that there will be a continuation of Williams ventures in health.
We believe the strategic combination of Akers with MyMD has the potential to accelerate the commercialization of MyMD’s drug development platform, which has been built over the past seven years,” said Chris Schreiber, Chief Executive Officer of Akers Biosciences, “MYMD-1 is targeting the underlying causes of chronic autoimmune diseases as well as aging itself, and SUPERA-1R–a patent-protected synthetic derivative of cannabidiol (CBD)–targeting numerous key cannabinoid receptors to address pain, anxiety, sleep disorders, and seizures. We look forward to closing the proposed business combination as soon as possible following the Meeting and will update shareholders at that time
Documentation will be forthcoming (for stockholders) that should be informative and important.
As has been revealed, Supera Pharma will be purchased by MyMD Pharma just before the final closing of the merger, for nearly 34 million MyMD Pharma shares, thus becoming an integral part of the new company. We have also become aware that a new private corporation was formed in FL this year under the name Nemo Life Sciences Inc., whose principal address is the suite in the Rangos Life Sciences Bldg on the Johns Hopkins campus where MyMD Pharmrceuticals is now located. A search of the internet indicated that NEMO is an integral part of the process of bone replacement and repair.
If that isn't enough, I have learned that another 10 (ten) private companies have been formed in FL this year by Jonnie and associates, all of which have as their principal address the same suite in Baltimore that MyMD Pharma occupies! They are,
Since MyMD has not yet announced any human studies to discuss, I thought it might be helpful to take a look at the proposed MILESTONE PAYMENTS in the merger agreement. It's difficult to grasp and seems to result in as many questions as it answers. The current market cap of AKER is close to 60 million. Attached is the Milestone Payment Agreement.
knuts4oe, grateful for your research - substantial findings validating my long-standing intuition that Williams is up to something important and that it will somehow (through underground hidden channels) make its way into the merger and finally emerge as an extraordinarily interesting MYMD.
This intuition is supported by occasional conversations with Patrick Cox, a researcher I respect, who keeps a good watch on what Williams is doing.
News 
Market Data 
Discover 
AI
